MedTrace Logo

Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma

NCT03490084 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-08-28

No results posted yet for this study

Summary

The study aims to compare the overall survival adjusted to quality of life of 2 groups of patients with multiple myeloma, depending on the type of care: (1) day hospitalization exclusively or (2) day hospitalization combined with hospital-at-home.

As secondary objectives, the study aims to compare the impacts of the two types of care organization on:

* the survival of patients and response to treatments according to criteria of the International Myeloma Working Group,
* psychological status of patients,
* specific toxicity related to treatment used (haematological and infectious toxicity, neurotoxicity, ...),
* health outcomes,
* the caregiver's burden,

This study is combined with a qualitative study about the incentives and the barriers, and in order to set up the patient's typology.

Conditions

Interventions

OTHER

Association of day hospitalization with hospital-at-home

Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.

OTHER

Day hospitalization exclusively

Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Bénédicte MITTAINE-MARZAC, PharmD · Hospitalisation à domicile (HAD), APHP

  • Matthieu de STAMPA, MD · Hospitalisation à domicile (HAD), APHP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2023-10-31
Completion
2023-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03490084 on ClinicalTrials.gov